Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $45
UBS Initiates Qiagen NV(QGEN.US) With Hold Rating
Baird Maintains Qiagen NV(QGEN.US) With Hold Rating, Raises Target Price to $43
Qiagen Analyst Ratings
BofA Securities Maintains Qiagen NV(QGEN.US) With Buy Rating, Cuts Target Price to $50
BofA Securities Cuts Price Target on Qiagen to $50 From $55, Maintains Buy Rating
UBS Maintains Qiagen NV(QGEN.US) With Hold Rating
William Blair Initiates Qiagen NV(QGEN.US) With Hold Rating
Deutsche Bank Maintains Qiagen NV(QGEN.US) With Buy Rating, Raises Target Price to $51.52
Qiagen (QGEN) Gets a Buy From Deutsche Bank
Jefferies Remains a Buy on Qiagen (QGEN)
TD Cowen Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $49
TD Cowen Keeps Their Hold Rating on Qiagen (QGEN)
Qiagen Analyst Ratings
Jefferies Maintains Qiagen NV(QGEN.US) With Buy Rating, Maintains Target Price $52
Berenberg Bank Maintains Qiagen NV(QGEN.US) With Buy Rating, Cuts Target Price to $50.23
Qiagen, Bio-Techne Downgraded at Baird Amid NIH Funding Concerns
Jefferies Maintains Qiagen NV(QGEN.US) With Buy Rating, Cuts Target Price to $52
Baird Downgrades Qiagen NV(QGEN.US) to Hold Rating, Cuts Target Price to $42
Qiagen Analyst Ratings